Live Breaking News & Updates on Respir Rev

Stay updated with breaking news from Respir rev. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative. | April 30, 2023 ....

Lisah Lancaster , Toby Maher , Christopher Keenan , Los Angeles , Drug Administration , Bexotegrast Clinical Development Next , University Of Southern California , Corporate Communications , Vanderbilt University Medical Center , Pliant Therapeutics Inc , European Medicines Agency , Group Demonstrated Treatment Effects Including Durable Improvements , Quantitative Lung Fibrosis , Well Tolerated , Percent Change , Cough Severity Visual Analog Scale , Baseline Over , Chief Medical Officer , Forced Vital Capacity , Idiopathic Pulmonary , Interstitial Lung Disease , Keck School , Southern California , Pliant Therapeutics , Private Securities Litigation Reform Act , Financial Condition ,

Pliant Therapeutics Announces Positive Long-Term Data from

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care. ....

Lisah Lancaster , Toby Maher , Los Angeles , Christopher Keenan , Group Demonstrated Treatment Effects Including Durable Improvements , Corporate Communications , Drug Administration , Vanderbilt University Medical Center , European Medicines Agency , Bexotegrast Clinical Development Next , Pliant Therapeutics Inc , University Of Southern California , Quantitative Lung Fibrosis , Well Tolerated , Percent Change , Cough Severity Visual Analog Scale , Baseline Over , Chief Medical Officer , Forced Vital Capacity , Idiopathic Pulmonary , Interstitial Lung Disease , Keck School , Southern California , Pliant Therapeutics , Private Securities Litigation Reform Act , Financial Condition ,

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative. | April 30, 2023 ....

Lisah Lancaster , Christopher Keenan , Los Angeles , Toby Maher , Drug Administration , Bexotegrast Clinical Development Next , Corporate Communications , Group Demonstrated Treatment Effects Including Durable Improvements , Keck School Of Medicine , Vanderbilt University Medical Center , University Of Southern California , Globenewswire Inc , Pliant Therapeutics Inc , European Medicines Agency , Quantitative Lung Fibrosis , Well Tolerated , Percent Change , Cough Severity Visual Analog Scale , Baseline Over , Chief Medical Officer , Forced Vital Capacity , Idiopathic Pulmonary , Interstitial Lung Disease , Southern California , Pliant Therapeutics , Private Securities Litigation Reform Act ,

The importance of managing mental health in COPD

Nurse respiratory specialist Karen Heslop-Marshall explains why patients with COPD are vulnerable to anxiety and depression. ....

City Of , United Kingdom , Newcastle Upon Tyne , Karen Heslop Marshall , Patient Health , Pbritish Thoracic Society , Royal College Of Psychiatrists , Global Initiative For Chronic Obstructive Lung Disease , Hospital Anxiety , General Anxiety Disease , Global Initiative , Chronic Obstructive Lung Disease , Tyne Hospitals , Intj Chron Obstruct Pulmon Dis , Database Syst Rev , Royal College , Inspiratory Resistive Loads , Chronic Obstructive Pulmonary , Relationship Between Anxiety , Treatment Adherence , Chronic Obstructive Pulmonary Disease , Ann Depress Anxiety , Respir Rev , Thoracic Society , Nursing Times , Pract Nurs ,

Persistent obstructive sleep apnoea in children: treatment options and management considerations

Unresolved obstructive sleep apnoea (OSA) after an adenotonsillectomy, henceforth
referred to as persistent OSA, is increasingly recognised in children (2–18 years).
Although associated with obesity, underlying medical complexity, and craniofacial
disorders, persistent OSA also occurs in otherwise healthy children. Inadequate treatment
of persistent OSA can lead to long-term adverse health outcomes beyond childhood.
Positive airway pressure, used as a one-size-fits-all primary management strategy
for persistent childhood OSA, is highly efficacious but has unacceptably low adherence
rates. ....

Cameroon General , United States , Acta Otolaryngol , Gerry Taylor , Strollo Jr , Balkissou Adamou , Pediatr Pulmonol , J Pediatr Otorhinolaryngol , Li Xinjun , J Orthod Dentofacial Orthop , American Heart Association , Paediatr Child Health , National Sleep Foundation , Lancet Digit Health , Englj Med , Head Neck Surg , Down Syndrome , Digit Health , American Heart , Clin Sleep Med , Respir Rev , Med Clin , Brain Res , Jappl Physiol , Child Health , Med Eng Technol ,